Broncus Holding (2216) Stock Overview
A medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
2216 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Broncus Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.56 |
| 52 Week High | HK$3.72 |
| 52 Week Low | HK$0.53 |
| Beta | 1.16 |
| 1 Month Change | -38.46% |
| 3 Month Change | -59.12% |
| 1 Year Change | -72.28% |
| 3 Year Change | -52.14% |
| 5 Year Change | n/a |
| Change since IPO | -96.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2216 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -12.5% | -0.9% | -3.2% |
| 1Y | -72.3% | -16.8% | -3.8% |
Return vs Industry: 2216 underperformed the Hong Kong Medical Equipment industry which returned -16.8% over the past year.
Return vs Market: 2216 underperformed the Hong Kong Market which returned -3.8% over the past year.
Price Volatility
| 2216 volatility | |
|---|---|
| 2216 Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2216 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2216's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 191 | Hong Xu | www.broncus.com |
Broncus Holding Corporation, a medical device company, focuses on the development and commercialization of interventional pulmonology medical devices in China and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; BroncTarget Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of acute COPD exacerbation management; H-Marker, a pulmonary surgical marker that can be used to mark the location of the lung nodule for positioning during surgical pneumonectomy; Mist Fountain, a disposable nebulizing micro-catheter for endoscope used for airway anaesthesia, precise antibacterial and anti-inflammatory, tuberculosis drug delivery, phlegm reduction and elimination, thoracic surgery staining location, etc.; and BroncTru, a disposable transbronchoscopic dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a real-time navigation within the airways for lung biopsy and other procedures; and LungPro System, an archimedes system.
Broncus Holding Corporation Fundamentals Summary
| 2216 fundamental statistics | |
|---|---|
| Market cap | HK$295.16m |
| Earnings (TTM) | -HK$140.21m |
| Revenue (TTM) | HK$1.36m |
Is 2216 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2216 income statement (TTM) | |
|---|---|
| Revenue | US$174.00k |
| Cost of Revenue | US$1.09m |
| Gross Profit | -US$917.00k |
| Other Expenses | US$16.96m |
| Earnings | -US$17.87m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | -527.01% |
| Net Profit Margin | -10,272.99% |
| Debt/Equity Ratio | 0.01% |
How did 2216 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/01 20:53 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Broncus Holding Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Nico Chen | DBS Bank Ltd |
| Yinglong Pan | Goldman Sachs |